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ABSTRACT
Disturbances in mineral metabolism play a central role in the development of renal bone disease. In a
54-wk, randomized, open-label study, 119 hemodialysis patients were enrolled to compare the effects of
sevelamer hydrochloride and calcium carbonate on bone. Biopsy-proven adynamic bone disease was the
most frequent bone abnormality at baseline (59%). Serum phosphorus, calcium, and intact parathyroid
hormone were well controlled in both groups, although calcium was consistently lower and intact
parathyroid hormone higher among patients who were randomly assigned to sevelamer. Compared with
baseline values, there were no changes in mineralization lag time or measures of bone turnover (e.g.,
activation frequency) after 1 yr in either group. Osteoid thickness significantly increased in both groups,
but there was no significant difference between them. Bone formation rate per bone surface, however,
significantly increased from baseline only in the sevelamer group (P  0.019). In addition, of those with
abnormal microarchitecture at baseline (i.e., trabecular separation), seven of 10 in the sevelamer group
normalized after 1 yr compared with zero of three in the calcium group. In summary, sevelamer resulted
in no statistically significant changes in bone turnover or mineralization compared with calcium carbon-
ate, but bone formation increased and trabecular architecture improved with sevelamer. Further studies
are required to assess whether these changes affect clinical outcomes, such as rates of fracture.
J Am Soc Nephrol 19: 405–412, 2008. doi: 10.1681/ASN.2006101089
Patients with chronic kidney disease (CKD) typi-
cally have abnormal bone histology. Alterations in
bone turnover, mineralization, and volume in renal
patients depend on several factors. In particular,
disturbances in calcium-phosphate, parathyroid
hormone (PTH), and vitamin D metabolism are
important in the development of renal osteodystro-
phy (ROD).
The pattern of ROD observed in patients with
stage 5 CKD has changed in recent years. Previ-
ously, observed bone conditions in renal patients in
order of prevalence were mixed uremic osteodys-
trophy (MUO), predominant hyperparathyroid
bone disease (HPBD), and aluminum-related os-
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teomalacia and adynamic bone disease (ABD); however, re-
duced use of aluminum has resulted in a decline in the occur-
rence of osteomalacia. Concurrently, there has been an
increase in ABD without aluminum toxicity and less MUO.1–3
This has been attributed to greater use of calcium-based phos-
phate binders, which may result in oversuppression of PTH,
especially when used with calcitriol or calcitriol analogues.4 – 6
Calcium-based binder use has also been linked with pro-
gression of vascular calcification.7 Evidence suggests that ABD
may predispose patients to soft tissue and vascular calcifica-
tion.8 The use of non– calcium-based phosphate binders, such
as sevelamer hydrochloride, may reduce the oversuppression
of PTH and so help prevent ABD and cardiovascular calcifica-
tions. Studies have shown that sevelamer attenuates progres-
sion of vascular calcification and prevents reduction in tho-
racic vertebral bone mineral density.7,9,10
Bone biopsy is the recognized gold standard for the diagno-
sis and evaluation of renal bone disease.11–13 Previous reports
assessing changes in vertebral bone with phosphate binders by
electron-beam tomography (EBT) did not assess changes in
bone histology.9,10 Thus, a study using bone biopsies was con-
ducted to compare the effects of sevelamer hydrochloride and
calcium carbonate on bone histology.
RESULTS
Disposition of patients is shown in Figure 1. A total of 119
patients were enrolled, 100 of whom had a baseline bone bi-
opsy. Ninety-one of these were randomly assigned to receive
sevelamer (n 44) or calcium-based binders (n 47), and 68
had a second bone biopsy after 1 yr (sevelamer n 33; calcium
n 35).
Baseline demographics and clinical characteristics were
comparable between groups (Table 1). Almost all patients
(98%) received calcium carbonate in the 30 d before screening,
with 93% treated with calcium-based binders as monotherapy.
Dosages of study medication increased in both groups dur-
ing the study. Mean daily sevelamer dosage increased from
3.3 2.0 to 5.0 2.7 g after 1 yr, and calcium increased from
3.8 2.2 to 4.0 2.5 g. Compliance assessed by pill count was
comparable between the treatment groups (sevelamer 92%;
calcium 95%). No patient received aluminum rescue therapy
for treatment-resistant hyperphosphatemia during the study.
None of the patients received parent vitamin D or ergo- or
cholecalciferol. At baseline, 14 (42%) patients in the sevelamer
group and 16 (46%) in the calcium group received active vita-
min D metabolites or analogs. All of these patients, with the
exception of one patient in the sevelamer group who received
-calcidiol for the duration of the study and one patient in the
calcium group who received paricalcitol for a 2-wk period,
were given calcitriol. The median weekly change in calcitriol or
analogue dosage significantly increased from baseline to end of
study in the sevelamer group compared with the calcium group
(2.0 versus0.0g intravenously, calcitriol or calcitriol equivalents;
P  0.027). An increase in vitamin dosage was possible in 19
(58%) patients who were treated with sevelamer compared with
11 (31%) patients who were treated with calcium. In general, both
treatments were well tolerated with adverse event profiles consis-
tent with patients’ underlying renal disease.
Biochemical Parameters
Biochemical parameters are summarized in Table 2. Serum
phosphorus levels were well controlled with both treatments
with no significant changes within or between groups (Figure
2A). Serum calcium and intact PTH (iPTH) were also well
controlled, and mean values remained within the recom-
mended Kidney Disease Outcomes Quality Initiative (K/
DOQI) ranges in both groups (Figure 2, B and C); however,
Enrolled, n = 119
Baseline bone biopsy, n = 100
Randomized, n = 91
No bone biopsy, n = 19
Excessive Al staining, n = 3
Unsuitable for histomorphometry, n = 6
Sevelamer, n = 44 Calcium, n = 47
Eligible for ITT analysis, n = 33* Eligible for ITT analysis, n = 35*
Early withdrawal 
from study, n = 10
Adverse event, n = 2
Withdrew consent, n = 2
kidney transplant, n = 4
Other, n = 2
Early withdrawal 
from study, n = 14
Adverse event, n = 2
Non-compliance, n = 1
Withdrew consent, n = 1
Kidney transplant, n = 8
Other, n = 2
Figure 1. Disposition of patients. The intention-to-treat (ITT) population was defined as all patients who were randomly assigned,
received one or more doses of study medication, and had a second bone biopsy. One patient in the sevelamer group completed
treatment but did not have a second bone biopsy and so was excluded from the ITT analysis. Two patients in the calcium group
withdrew from the study early but received one or more doses of study medication and had a second bone biopsy and so were included
in the ITT analysis.
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serum calcium was consistently lower whereas serum iPTH
was consistently higher with sevelamer. Serum 25-OH D and
1,25-OH2 D levels were low at baseline in both groups, and small
but comparable median increases from baseline were observed
with both sevelamer and calcium (2.2 versus 1.9 ng/ml [P 0.53]
and 1.7 versus 0.2 ng/ml [P 0.27], respectively). Total and LDL
cholesterol significantly decreased within the sevelamer but not
the calcium group, and the difference between treatments was
significant (total cholesterol P 0.03; LDL cholesterol P 0.01).
HDL cholesterol increased in both groups similarly, without dif-
ference between groups. Serum bicarbonate levels were similar in
both groups at all time points.
Serum bone-specific alkaline phosphatase (BSAP) signifi-
cantly increased from baseline at 6 mo (P 0.001) and at 1 yr
(P 0.02) with sevelamer but not calcium, but there were no
differences between groups at either time point. Osteocalcin
increased significantly from baseline in the calcium group, but
there was no significant difference between treatments. Serum
Table 1. Baseline characteristicsa
Characteristic Sevelamer (n  33) Calcium (n  35) P
Gender (M/F; n %) 22/11 (67/33) 18/17 (51/49) 0.23
Race 0.99
white 32 (97) 34 (97)
black 1 (3) 1 (3)
Age (yr; mean  SD) 55.5  15.4 53.9  13.7 0.53
Menopausal status (n %) 0.0097
premenopausal 0 (0) 8 (47)
postmenopausal 11 (100) 9 (53)
BMI (kg/m2; mean  SD) 23.5  3.5 25.3  3.8 0.09
Smoker (n %) 8 (24) 3 (9) 0.10
Diabetes (n %) 2 (6) 8 (23) 0.08
Hypertension (n %) 24 (73) 25 (71) 0.99
Primary cause of stage 5 CKD (n %) 0.18
hypertension 2 (6.1) 6 (17.1)
glomerulonephritis 8 (24.2) 7 (20.0)
diabetes 2 (6.1) 7 (20.0)
pyelonephritis 3 (9.1) 3 (8.6)
polycystic kidneys 3 (9.1) 2 (5.7)
interstitial nephrosis 4 (12.1) 0 (0)
other 11 (33.3) 10 (28.6)
Dialysis vintage (mo; median range) 23 (4 to 222) 25 (2 to 181) 0.49
Phosphate binder use (in 30 d before screening; n %) 33 (100) 35 (100) 0.07
calcium carbonate 31 (94) 32 (91)
sevelamer 1 (3) 1 (3)
calcium carbonate  sevelamer 1 (3) 0 (0)
calcium carbonate  aluminum 0 (0) 2 (6)
Vitamin D use (in 12 mo before screening; n [%]) 22 (67) 24 (69) 1.0
aBMI, body mass index.
Table 2. Changes in serum biochemical parameters
Parameter
Sevelamer (n  33) Calcium (n  35)
Pa
Baseline 1 Yr Baseline 1 Yr
Phosphorus (mg/dl; mean  SD) 5.8  1.5 5.4  0.1.4 5.7  1.8 5.3  1.9 0.78
Calcium (mg/dl; mean  SD) 9.6  0.7 9.1  1.1 9.8  1.0 9.3  0.7b 0.22
iPTH (pg/ml; median range) 167 (3 to 1958) 275 (34 to 3890) 113 (4 to 1369) 227 (28 to 3636)b 0.55
25-OH D (ng/ml; median range) 16.3 (5.0 to 34.6) 20.0 (5.4 to 53.2)b 16.6 (5.0 to 35.3) 17.4 (5.0 to 49.1) 0.53
1,25-OH2 D (pg/ml; median range) 6.4 (5.0 to 22.4) 8.1 (4.5 to 83.5) 11.8 (5.0 to 42.9) 13.7 (4.5 to 61.5) 0.27
Total cholesterol (g/L; mean  SD) 1.65  0.38 1.40  0.34b 1.72  0.41 1.66  0.41 0.03
LDL cholesterol (g/L; mean  SD) 1.03  0.34 0.68  0.30b 1.07  0.37 1.00  0.31 0.01
HDL cholesterol (g/L; mean  SD) 0.50  0.12 0.55  0.14b 0.43  0.12 0.49  0.15b 0.87
Bicarbonate (mmol/L; mean  SD) 19.3  3.9 20.4  3.3 19.7  3.8 21.2  4.1 0.34
BSAP (g/L; median range) 11.5 (3.9 to 65.2) 19.1 (3.9 to 174.0)b 10.6 (3.4 to 80.1) 12.7 (4.5 to 185.0) 0.19
Osteocalcin (ng/ml; median range) 68.5 (2.9 to 896) 84.2 (15.2 to 595) 45.8 (2.4 to 308) 123 (7.6 to 1122)b 0.54
N-telopeptides (nM; median range) 135 (7 to 1200) 298 (11 to 1200)b 72 (8 to 1200) 132 (10 to 1200)b 0.87
aBetween-group difference in change from baseline assessed using Wilcoxon rank sum test.
bP  0.05 for within-group change from baseline assessed using Wilcoxon signed rank test. Initial lipid levels measured at screening, not baseline.
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N-telopeptide increased significantly from baseline in both
groups but without significant between-group differences.
Bone Turnover and Mineralization
Changes in parameters of bone mineralization and turnover
are summarized in Table 3. Mineralization lag time was com-
parable between groups at baseline and 1 yr with no significant
changes within or between groups. Osteoid thickness signifi-
cantly increased in both groups with no significant between-
group differences in change from baseline.
There were no significant changes within or between groups
in activation frequency (Acf), number of osteoblasts/bone pe-
rimeter, or number of osteoclasts/bone perimeter. Bone for-
mation rate/bone surface significantly increased from baseline
in the sevelamer group (P  0.019) but not in the calcium
group. At baseline, three patients were excluded from the study
because of stainable aluminum at20% of the trabecular sur-
face, and there were no patients with stainable bone aluminum
at end of the study.
Trabecular Architecture
Cancellous bone volume was significantly higher in the cal-
cium group than in the sevelamer group at baseline (P 
0.033) and 1 yr (P  0.029), but there were no significant
changes from baseline within (sevelamer P  0.09; calcium
P 0.11) or between groups. Trabecular thickness was signif-
icantly higher in the calcium group (P  0.02) at baseline,
although below normal in both groups. There was no differ-
ence in change from baseline between groups after 1 yr. Tra-
becular separation, a parameter indicating connection be-
tween trabeculae that is microarchitecture of cancellous bone,
was comparable between groups at baseline and 1 yr with no
significant differences in change from baseline within or be-
tween groups. The majority of patients had normal trabecular
separation at baseline (sevelamer 67%; calcium 74%). In pa-
tients with abnormally high (550 m) baseline trabecular
separation, seven of 10 patients in the sevelamer group had
normal trabecular separation after 1 yr, whereas separation
remained550 m in all three calcium patients (P 0.07).
Shifts between Groups of Renal Bone Disease
At baseline, ABD was the most frequent condition in both the
sevelamer (n  22; 67%) and calcium (n  20; 57%) groups.
Severe predominant HPBD was diagnosed in four (12%) pa-
tients in the sevelamer group and five (14%) in the calcium
group. Mild to moderate HPBD was found in six (18%) pa-
tients in the sevelamer group and eight (23%) patients in the
calcium group. One patient in each group had MUO. Only a
single patient, in the calcium group, had osteomalacia.
At the end of the study, three (9%) patients in the sevelamer
group fell to the ABD category (from severe HPBD [n  1],
from mild to moderate HPBD [n  1], and from MUO [n 
1]). In contrast, in the calcium group, nine (26%) patients fell
to a lower bone turnover category (from severe HPBD to mild
to moderate HPBD [n 3], from mild to moderate HPBD to
ABD [n 5], and from MUO to ABD [n 1]; Figure 3). The
majority of patients still had ABD, and no patient developed
osteomalacia.
DISCUSSION
A high prevalence of ABD was observed in this study, with
almost 60% of patients having an Acf 0.49/yr at baseline.
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Figure 2. Serum phosphorus (A), serum calcium (B), and serum
iPTH (C) during 1 yr of treatment with sevelamer or calcium.
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This is consistent with reports of increasing prevalence of ABD
in the past two decades,1–3 an increase that has coincided with
the widespread use of calcium-based binders combined with
more aggressive use of vitamin D analogs.4,5 Excluding patients
with serum phosphorus values8.1 mg/dl could not have had
a major influence on these results because only two patients
were excluded because of such severe hyperphosphatemia.
Importantly, the high prevalence of ABD was observed de-
spite most patients’ being treated in accordance with K/DOQI
guidelines and having serum mineral parameters within rec-
ommended ranges.11 Almost all (98%) patients were on cal-
cium carbonate before the study, 65% had received calcitriol,
and average dialysis vintage was3.5 yr. This may explain why
median serum iPTH levels were relatively low (150 to 300 pg/
ml) at baseline. The frequent observation of ABD with median
PTH values of 150 to 400 pg/ml in this study reaffirms the value
of bone biopsies during dialysis in patients with intermediate
PTH values.14
Although there were no differences between groups, bone
formation rate significantly increased from baseline in the
sevelamer group but not the calcium group. Moreover, seven
of 10 sevelamer patients with abnormally high baseline trabec-
ular separation moved into normal range compared with none
of the calcium-treated patients (P 0.07). BSAP, an index of
bone formation, increased from baseline in the sevelamer
group, whereas N-telopeptide, a parameter of bone resorption,
increased in both treatment groups. This indicates that the
osteocalcin increase seen in the calcium group is mainly reflec-
tive of increased bone resorption with the accompanied release
of osteocalcin from bone. Effects of sevelamer and calcium on
bone mineralization were comparable.
Although some changes in histomorphometric parameters
were suggestive of increased bone turnover with sevelamer,
most (53%) patients still had ABD after 1 yr of treatment with
no differences between groups with regard to change in bone
disease classification. This is consistent with the intransigent
nature of ABD, which, once established, means that any im-
provements in bone histology occur very slowly; however,
changes in biochemical parameters may forecast improve-
ments in bone histology. Interpretation of biochemical mark-
ers of bone is limited when the markers are renally excreted.
This applies to osteocalcin and N-telopeptides, whereas BSAP
is not retained in CKD.
Previous studies have suggested that sevelamer may have a
positive effect on bone mass and turnover compared with cal-
Table 3. Changes in bone mineralization, bone turnover, and trabecular architecturea
Parameter
Sevelamer (n  33) Calcium (n  35)
P b
Baseline 1 Yr Baseline 1 Yr
Bone mineralization
mineralization lag time in
lamellar bone (d)
28.2 (9.4 to 175.9) 36.1 (0 to 153.7) 26.1 (0.4 to 155.0) 40.8 (2.4 to 493.8) 0.54
osteoid thickness (m) 9.3 (3.8 to 37.7) 10.5 (4.8 to 16.5)c 9.6 (4.1 to 24.0) 10.7 (5.7 to 27.8)d 0.71
Bone turnover
Acf (/yr) 0.36 (0.04 to 1.84) 0.43 (0.02 to 2.41) 0.39 (0 to 1.54) 0.45 (0 to 1.97) 0.76
bone formation rate/bone
surface (mm3/cm2 per yr)
1.6 (0.1 to 8.8) 2.3 (0.2 to 13.9)e 2.1 (0 to 8.5) 2.5 (0.4 to 14.0) 0.82
no. of osteoblasts/bone
perimeter (/100 mm)
136.0 (0 to 882.5) 148.2 (2.8 to 1690.6) 87.2 (3.1 to 1109.7) 180.8 (6.4 to 1268.1) 0.99
no. of osteoclasts/bone
perimeter (/100 mm)




18.4 (0.2 to 66.9) 19.8 (10.9 to 38.9) 21.7 (11.2 to 35.0) 24.0 (11.5 to 59.1) 0.10
trabecular thickness (m) 105.7 (1.7 to 144.6) 106.7 (70.5 to 191.9) 119.1 (62.6 to 171.7) 114.7 (0.6 to 188.2) 0.96
trabecular separation (m) 486.2 (11.8 to 773.5) 466.5 (229.6 to 841.6) 418.4 (247.7 to 963.9) 385.0 (3.3 to 671.4) 0.46
aData are median (range).
bBetween-group difference in change from baseline.
cP  0.030 versus baseline.
dP  0.026 versus baseline.
eP  0.019 versus baseline.
 
Severe 
HPBD (n = 4)
Mild-to-Moderate
HPBD (n = 6)
MUO (n = 1)
ABD (n = 22)
OM (n = 0)
Severe 
HPBD (n = 7)
Mild-to-Moderate
HPBD (n = 6)
MUO (n = 2)
ABD (n = 18)
OM (n = 0)
Sevelamer (n = 33)
Baseline End of Study
Severe 
HPBD (n = 5)
Mild-to-Moderate
HPBD (n = 8)
MUO (n = 1)
ABD (n = 20)
OM (n = 1)
Severe 
HPBD (n = 3)
Mild-to-Moderate
HPBD (n = 11)
MUO (n = 2)
ABD (n = 19)
OM (n = 0)
Baseline End of Study
Calcium (n = 35)
Figure 3. Changes in types of bone disease (based on qualita-
tive evaluation of bone). OM, osteomalacia.
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cium. In a 1-yr randomized trial of 111 hemodialysis patients,
calcium treatment resulted in a significant reduction in tho-
racic vertebral bone mineral density as measured by EBT com-
pared with sevelamer.9 Calcium was also associated with lower
levels of PTH, BSAP, and osteocalcin. Although bone biopsies
were not performed, these results suggest that calcium-treated
patients may have been more likely to develop adynamic bone
than sevelamer-treated patients. Similar findings after 2 yr
were reported by Asmus et al.10 Moreover, a study of 28 hemo-
dialysis patients with ABD reported that switching treatment
from calcium to sevelamer resulted in biochemical changes,
suggesting improved bone turnover in 18% of patients after 6
mo and 32% of patients after 1 yr.15
It has been reported that low bone turnover predisposes to
the development of extraosseous calcifications.8 Vascular cal-
cification is common in CKD and is a predictor of all-cause and
cardiovascular mortality.16 –18 Similarly, reduced bone mass
has been shown to predict mortality risk in long-term hemo-
dialysis patients.19 Using EBT, an inverse relationship between
bone density and extent of vascular calcification has been ob-
served in patients on hemodialysis.9,20
25-OH D and 1,25-OH2 D were low at baseline and end of
the study in both treatment groups. The use of calcitriol or
vitamin D analogs was higher in the sevelamer group than in
the calcium group, with a significantly greater increase in
change in median weekly dosage and more patients with an
increase in dosage. 25-OH D blood levels did not fall in either
group, indicating that there was no binding of 25-OH D by
sevelamer. Although well controlled in both groups, mean se-
rum calcium was consistently lower with sevelamer, which
may explain the greater use of vitamin D analogs in this group.
Increased vitamin D use together with higher PTH levels could
explain the increased bone formation rates seen with sevel-
amer. Retrospective studies have suggested that use of calcitriol
or paricalcitriol may be associated with reduced cardiovascular
mortality and a survival advantage in patients who are on di-
alysis.21,22 The potential for increased use of calcitriol or vita-
min D analogs in patients who are treated with sevelamer may
thus be associated with important clinical benefits.
In summary, this study shows that phosphate control with
sevelamer resulted in no statistically significant changes in
bone turnover or bone mineralization compared with calci-
um-based binders; however, bone formation was significantly
increased with sevelamer, which was associated with improved
trabecular architecture. Further studies are required to assess
whether increased bone formation results in higher bone vol-
ume and reduced fracture rates.
CONCISE METHODS
This was a 54-wk, randomized, open-label study to compare the ef-
fects of sevelamer hydrochloride and calcium carbonate on bone
turnover, mineralization, and volume. Adult patients (18 yr) who
were on hemodialysis 3 times/wk (3 mo) and stable serum phos-
phorus8.1 mg/dl (2.6 mmol/L) for1 mo before screening and
were receiving treatment with a phosphate binder were enrolled at 16
centers in Portugal. Patients were required to have stable serum phos-
phorus 8.1 mg/dl (2.6 mmol/L) because higher levels were con-
sidered indicative of noncompliance with phosphate binder therapy.
Other exclusion criteria included use of aluminum-based binders in
the previous year (3 consecutive months), treatment with medica-
tions that are known to affect bone metabolism (e.g., corticosteroids,
antiseizure or thyroid agents, bisphosphonate, calcitonin), tetracy-
cline allergy, alcohol or drug abuse, and any significant concurrent
clinical condition. The use of aluminum- or magnesium-based ant-
acids was not permitted during the study, with the exception of alu-
minum rescue therapy (maximum 4 wk) for treatment-resistant hy-
perphosphatemia. The use of calcium other than prescribed as study
drug was not permitted. Written informed consent was obtained
from all patients, and the study was conducted in accordance with the
Declaration of Helsinki and approved by independent ethics commit-
tees at each of the participating centers.
Study Design
At screening, patients underwent physical examination and review of
medical history and previous medication. Within 3 wk of screening,
eligible patients had baseline transiliac bone biopsies taken from the
right or left anterior iliac crest in an alternating manner after double
tetracycline labeling of bone. Patients who had 20% stainable alu-
minum (aurin tricarboxylic acid stain) at the trabecular surface and
whose biopsy was suitable for histomorphometry were stratified ac-
cording to qualitatively assessed bone turnover (high versus low/nor-
mal) and randomly assigned to treatment with either sevelamer or
calcium in a 1:1 manner. Randomization was performed centrally by
an independent study coordinator, with a maximum period of 6 wk
allowed between bone biopsy and start of treatment.
During the 54-wk treatment phase, patients received sevelamer
hydrochloride (Renagel 800-mg tablets; Genzyme, Cambridge, MA)
or calcium carbonate (Salusif 500- or 1000-mg tablets; Lab de Produ-
tos Quı´micos e Farmaceˆuticos Lda, Lisbon, Portugal) three times a
day with meals. Number of tablets per meal could be adjusted to
reflect phosphorus content of the meal, as long as the daily dosage was
maintained. Starting dosage was individualized by substituting the
phosphate binder used by the patient at screening with sevelamer or
calcium on a gram-per-gram basis. Two weeks after randomization
and every 4 wk thereafter, serum phosphorus, calcium, and iPTH
were assessed together with adverse events and any changes in con-
comitant medication. When required, the dosage of phosphate binder
was titrated to achieve a serum phosphorus of 3.2 to 5.0 mg/dl (1.00 to
1.60 mmol/L). Serum calcium (adjusted for albumin) was maintained
at10.4 mg/dl (2.60 mmol/L) by adjustment of calcitriol or calcit-
riol analogue and/or calcium dosage if necessary. Calcitriol and cal-
citriol analogue treatment could also be titrated to maintain levels of
serum iPTH at 150 to 300 pg/ml. The choice of vitamin D compound
to be used was not specified and was at the discretion of the individual
physician. No parent vitamin D or calcidiol was given. At the end of
treatment, a second bone biopsy, from the iliac crest of the opposite
site, was performed.
As in previous studies of sevelamer, neither clinical investigators
nor patients were blinded to treatment because it would have been
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possible to identify by the lower incidence of hypercalcemia and de-
crease in serum LDL cholesterol associated with sevelamer. Differ-
ences in taste, smell, and appearance of tablets may also have resulted
in identification of treatment modality. Compliance was assessed by
pill counts.
Bone Biopsies, Mineralized Bone Histology, and Bone
Morphometry
Bone biopsies were taken at baseline and end of study. For double
labeling of bone, patients received oral tetracycline hydrochloride 500
mg twice daily for 2 d followed by a 10-d tetracycline-free interval and
another course of tetracycline hydrochloride at the same dosage for
4 d. Transiliac bone biopsies were performed after an additional 4 d
with bone samples (0.5 cm diameter 1 to 2 cm length) being taken
from the anterior iliac crest. All bone biopsies were performed at
designated study centers in Lisbon (A.F.) and Porto (J.M.F.).
Iliac crest bone samples were fixed with ethanol at room temper-
ature, dehydrated, and embedded in methylmethacrylate as described
previously.13 Serial sections of 3- and 7-m thickness were cut with a
Microm microtome equipped with a carbide-edged knife (HM360;
Microm, Walldorf, Germany). Sections were stained with the modi-
fied Masson-Goldner trichrome stain,23 the aurin tricarboxylic acid
stain,24 and solochrome azurine,25 used to demonstrate the extent of
aluminum deposits at the bone-osteoid interface. Unstained sections
were prepared for phase-contrast and fluorescence light microscopy.
Qualitative assessment of bone was performed at the study start to
stratify patients by bone turnover status before randomization and at
the study end to categorize patients by renal bone disease type. In
addition, at the end of the study, histomorphometry for static and
dynamic parameters of bone structure, formation, and resorption
using the Osteoplan II system (C. Zeiss, New York, NY) was done at a
magnification of 200. All bone samples were processed and ana-
lyzed at the Bone Diagnostic and Research Laboratory, University of
Kentucky Medical Center (Lexington, KY), without knowledge of the
treatment arm. All parameters were in compliance with the recom-
mendations of the nomenclature committee of the American Society
of Bone and Mineral Research.26
The primary efficacy end points were (1) changes from baseline in
mineralization lag time in lamellar bone and osteoid thickness and (2)
changes in bone turnover as measured by Acf, number of osteoblasts/
bone perimeter, number of osteoclasts/bone perimeter, and bone for-
mation rate/bone surface. Secondary end points were the percentages
of patients who developed (1) osteomalacia (mineralization lag time
100 d and osteoid thickness 20 m),13 (2) predominant HPBD
(Acf 0.72/yr, presence of woven osteoid and fibrosis, osteoblasts
200/100 mm, and osteoclasts 53/100 mm), and (3) ABD (Acf
0.49/yr and osteoid thickness 20 m). Changes from baseline in
trabecular microarchitecture (cancellous bone volume, trabecular
thickness, and trabecular separation) were also assessed.
Blood samples were taken before dialysis (at screening, 6 mo, and
1 yr) and assessed at a central laboratory (Laboratorio de Ana´lisis, Dr.
Echevarne, Barcelona, Spain). Serum phosphorus, calcium (adjusted
for albumin), iPTH (Immulite 2500 Intact PTH; Diagnostics Prod-
ucts Corp., Madrid, Spain), and bicarbonate were measured at screen-
ing, baseline, randomization, 2 wk after randomization, and then ev-
ery 4 wk until the end of the study. Vitamin D (25-OH D and 1,25-
OH2 D; RIA, Sorin Biomedica, Barcelona, Spain), BSAP (RIA, IZASA,
Madrid, Spain), osteocalcin (RIA, IZASA), and N-telopeptide (type 1
collagen; ELISA; Ortho-Clinical Diagnostics, Buckinghamshire, UK)
were measured at baseline, 6 mo, and 1 yr.
Statistical Analyses
Acf was chosen for determination of sample size because it has the
largest variance among the studied histomorphometric parameters.
On this basis, it was estimated that a sample size of 32 patients would
provide 97% power to detect a significant difference (P  0.01) be-
tween treatments, based on the assumption that 0.16/yr (within-
group SD 0.08) is the smallest difference that would be considered
clinically meaningful; however, because a high dropout rate was ex-
pected, a target enrollment of 100 patients was selected.
Baseline characteristics were compared between groups using the
Wilcoxon rank sum test for continuous variables and Fisher exact test
for categorical variables. When any baseline characteristics were sig-
nificantly different between groups, an adjusted treatment difference
in the change from baseline to end of study was provided based on
multiple linear regression models. Changes from baseline to end of
study were assessed using Wilcoxon signed rank tests and compared
between groups using the Wilcoxon rank sum test for continuous
variables and Fisher exact test for categorical variables. All probability
tests were two-sided and tested at the   0.05 level of significance.
The primary population for the analysis was the intent-to-treat pop-
ulation, which included all patients who were randomly assigned,
received one or more doses of study medication, and had a second
bone biopsy.
ACKNOWLEDGMENTS
This study was supported by Genzyme Corp.
Data from this study were presented at the XLIII Congress of the
European Renal Association–European Dialysis and Transplant As-
sociation; July 15 through 18, 2006; Glasgow, UK.
Other members of the Sevelamer Study Group were Patricia Mar-
tins, Centro Renal da Prelada, Porto; Antonio Morais Sarmento,
CMDR-Centro Me´dico Doenc¸as Renais, Porto; Jorge Dickson, So-
ciedade Portuguesa de Dia´lise Amadora, Amadora; Berta De Car-
valho, UniNefro, Sto. Tirso; Odete Pereira, Nefronorte-Centro Renal
do Norte em Paredes’ Paredes; Ana Ventura, NefroNorte-Centro Re-
nal da Re´gua-Peso da Re´gua, Peso da Re´gua; and Vasco Miranda,
Dinefro, Maia.
We thank Guodong Wang, Richard M. Wheaton, and Juliana Van
Willigen for excellent technical support.
DISCLOSURES
A.F. is a member of a speaker bureau for Genzyme Corp. and an advisor for
Abbott; J.M.F. is a consultant for Genzyme Portugal and Amgen Portugal;
R.M.H. and A.D. are employees of Genzyme Corp.
CLINICAL RESEARCHwww.jasn.org
J Am Soc Nephrol 19: 405–412, 2008 Effect of Sevelamer on Renal Osteodystrophy 411
REFERENCES
1. Monier-Faugere MC, Malluche HH: Trends in renal osteodystrophy: A
survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial
Transplant 11[Suppl 3]: 111–120, 1996
2. Couttenye MM, D’Haese PC, Deng JT, Van Hoof VO, Verpooten GA,
De Broe ME: High prevalence of adynamic bone disease diagnosed
by biochemical markers in a wide sample of the European CAPD
population. Nephrol Dial Transplant 12: 2144–2150, 1997
3. Malluche HH, Mawad H, Monier-Faugere MC: The importance of
bone health in end-stage renal disease: Out of the frying pan, into the
fire? Nephrol Dial Transplant 19[Suppl 1]: i9–i13, 2004
4. Malluche HH, Monier-Faugere MC: Risk of adynamic bone disease in
dialyzed patients. Kidney Int Suppl 38: S62–S67, 1992
5. Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton
S, Sherrard D: Risk factors for renal osteodystrophy: A multivariant
analysis. J Bone Miner Res 10: 149–156, 1995
6. Cannata Andia JB: Adynamic bone and chronic renal failure: An over-
view. Am J Med Sci 320: 81–84, 2000
7. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group:
Sevelamer attenuates the progression of coronary and aortic calcifi-
cation in hemodialysis patients. Kidney Int 62: 245–252, 2002
8. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Verne-
joul MC: Arterial calcifications and bone histomorphometry in end-
stage renal disease. J Am Soc Nephrol 15: 1943–1951, 2004
9. Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H,
Braun J, Chertow GM: Decrease in thoracic vertebral bone attenuation
with calcium-based phosphate binders in hemodialysis. J Bone Miner
Res 20: 764–772, 2005
10. Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W,
Neumayer HH, Raggi P, Bommer J: Two year comparison of sevelamer
and calcium carbonate effects on cardiovascular calcification and
bone density. Nephrol Dial Transplant 20: 1653–1661, 2005
11. National Kidney Foundation: K/DOQI clinical practice guidelines for
bone metabolism and disease in chronic kidney disease. Am J Kidney
Dis 42[Suppl 3]: S1–S201, 2003
12. Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman
C, Malluche HH, McCarthy JT, Massry SG, Mehls O, Salusky IB, Silver
JM, Smogorzewski MT, Slatopolsky EM, McCann L, Bone Turnover
Work Group: Diagnosis, assessment, and treatment of bone turnover
abnormalities in renal osteodystrophy. Am J Kidney Dis 43: 558–565,
2004
13. Malluche HH, Faugere MC: Atlas of Mineralized Bone Histology, New
York, Karger, 1986
14. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH: Predictive value
of serum parathyroid hormone levels for bone turnover in patients
on chronic maintenance dialysis. Am J Kidney Dis 26: 622–631,
1995
15. Hyodo T, Wakai H, Takemura T, Taira T, Hidai H, Tsuchida M, Fujita T,
Yoshida K, Baba S, Sakai T: Treatment of adynamic bone disease with
the complete replacement from calcium carbonate to sevelamer hy-
drochloride [in Japanese]. Clin Calcium 15[Suppl 1]: 15–22, 2005
16. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial
calcifications, arterial stiffness, and cardiovascular risk in end-stage
renal disease. Hypertension 38: 938–942, 2001
17. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H:
Arterial media calcification in end-stage renal disease: impact on
all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:
1731–1740, 2003
18. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Goncalves M,
Negrao AP: A simple vascular calcification score predicts cardiovas-
cular risk in haemodialysis patients. Nephrol Dial Transplant 19: 1480–
1488, 2004
19. Taal MW, Roe S, Masud T, Green D, Porter C, Cassidy MJ: Total hip
bone mass predicts survival in chronic hemodialysis patients. Kidney
Int 63: 1116–1120, 2003
20. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC:
Electron beam computed tomography in the evaluation of cardiac
calcification in chronic dialysis patients. Am J Kidney Dis 27: 394–401,
1996
21. Shoji T, Nishizawa Y: Vitamin D and survival of hemodialysis patients
[in Japanese]. Clin Calcium 14: 64–68, 2004
22. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA
Jr, Thadhani R: Activated injectable vitamin D and hemodialysis sur-
vival: A historical cohort study. J Am Soc Nephrol 16: 1115–1125,
2005
23. Goldner J: A modification of the Masson trichrome technique for
routine laboratory purposes. Am J Pathol 14: 237–243, 1938
24. Lillie PD, Fullmer HM: Histopathologic Technique and Practical Histo-
chemistry, 4th Ed., New York, McGraw Hill, 1976
25. Denton J, Freemont AJ, Ball J: Detection of distribution of aluminium
in bone. J Clin Pathol 37: 136–142, 1984
26. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche HH, Meunier
PJ, Ott SM, Recker RR: Bone histomorphometry: Standardization of
nomenclature, symbols, and units. J Bone Miner Res 2: 595–610, 1987
CLINICAL RESEARCH www.jasn.org
412 Journal of the American Society of Nephrology J Am Soc Nephrol 19: 405–412, 2008
